The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 247 consecutive cases

Autoimmunity Reviews

Volumn 14, Issue 5, 2015, Pages 387-395

  Alijotas Reig, Jaume ^a,b   Ferrer Oliveras, Raquel ^a   Ruffatti, Amelia ^c   Tincani, Angela ^d   Lefkou, Elmina ^e   Bertero, Ma Tiziana ^f   Coloma Bazan, Emmanuel ^g   de Carolis, Sara ^h   Espinosa, Gerard ^g   Rovere Querini, Patrizia ⁱ   Kuzenko, Anna ^f   Valverde, Enrique E ^j   Robles, Angel ^k   Cervera, Ricard ^g   Canti, Valentina ^c   Fredi, Micaela ^d   Gil Aguado, Antonio ^k   Lundelin, Krista ^l   Llurba, Elisa ^a   Melnychuk, Taisiya ^a   Nalli, Cecilia ^d   Picardo, Elisa ^m   Silvestro, Erika ^f   del Ross, Teresa ^c   Farran Codina, Inmaculada ^a   more..

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF PADOVA   (Italy)

^d Ospedale Civile   (Italy)

^e Aristotle University of Thessaloniki   (Greece)

^f Department of Clinical Immunology ^*  (Italy)

^g UNIVERSITY OF BARCELONA   (Spain)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j Althaia   (Spain)

^k HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^l TURKU UNIVERSITY HOSPITAL   (Finland)

^m UNIVERSITY OF TURIN   (Italy)

more..

Author keywords

Antiphospholipid antibody; Laboratory categories; Obstetric antiphospholipid syndrome; Obstetric morbidity; Registry; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; COMPLEMENT; ENOXAPARIN; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FALSE NEGATIVE RESULT; FEMALE; FETUS WASTAGE; HELLP SYNDROME; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LIVE BIRTH; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PUERPERIUM; REGISTER; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; DISEASE COURSE; IMMUNOLOGY; PREGNANCY COMPLICATION; RISK FACTOR;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; DISEASE PROGRESSION; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; REGISTRIES; RISK FACTORS;

EID: 84925140284     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.12.010     Document Type: Review

References (48)

1. Antiphospholipid syndrome. ACOG Practice Bulletin. Obstet Gynecol 2012, 120:1514-1521.
2. Alijotas-Reig J., Ferrer-Oliveras R. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a preliminary first year report. Lupus 2012, 21:766-768. EUROAPS Study Group.
3. Out H.J., Kooijman C.D., Bruinse H.W., Derksen R.H. Histopathological findings in placentae from patients with intra-uterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynaecol Rep Biol 1991, 195:211-220.
4. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid-induced fetal loss by inhibiting complement activation. Nat Med 2004, 10:1222-1226.
5. Carbone J., Sarmiento E., Rodriguez-Molina J., Fernandez-Cruz E. Hipocomplementemia C3 y C4 en el síndrome antifosfolípido obstétrico. Rev Clin Esp 2008, 208:168-171.
6. Salmon J.E., Girardi G. Antiphospholipid syndrome revisited: a disorder initiated by inflammation. Lupus 2007, 16(abst suppl.):1-2.
7. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid-induced fetal loss by inhibiting complement activation. Nat Med 2004, 10:1222-1226.
8. Berman J., Girardi G., Salmon J.E. TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005, 174:1222-1226.
9. Girardi G., Yarilin D., Thurman J.M., Holers V.M., Salmon J.E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006, 203:2165-2175.
10. Branch W. Obstetric Task Force report of the obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010. Lupus 2011, 20:158-164.
11. Alijotas-Reig J., Vilardell-Tarres M. Is obstetric antiphospholipid syndrome a primary nonthrombotic, proinflammatory, complement-mediated disorder related to antiphospholipid antibodies?. Obstet Gynecol Surv 2010, 65:39-45.
12. Levy R.A., Jesus G.R.R., Jesus N.R. Obstetric antiphospholipid syndrome: still a challenge. Lupus 2010, 19:457-459.
13. Alijotas Reig J. Towards the comprehension of heterogeneity of clinical manifestations related to antiphospholipid antibodies. Med Clin (Barc) 2005, 125:187-189.
14. de Jesus G.R., Agmon-Levin N., Andrade CA Carlos A., Andreoli L., Chighizola C.B., Porter T.F., et al. 14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev 2014, 13:795-813.
15. Yamada H., Atsumi T., Kato E.H., Shimada S., Morikawa M., Minakami H. Prevalence of diverse antiphospholipid antibodies in women with recurrent spontaneous abortion. Fertil Steril 2003, 80:1276-1278. [1310].
16. Mekinian A., Loire-Berson P., Nicaise-Roland P., Lachassinne E., Stirnemann J., Boffa M.C., et al. Outcomes and treatment of obstetrical antiphospholipid syndrome in women with low antiphospholipid antibody levels. J Reprod Immunol 2012, 94:222-226.
17. Andreoli L., Tincani A. Beyond the "syndrome": antiphospholipid antibodies as risk factors. Arthritis Rheum 2012, 64:342-345.
18. Sater M.S., Finan R.R., Abu-Hijleh F.M., Almawi W.Y. Anti-phosphatidylserine, anti-cardiolopin, anti-B2glycoprotein I, and anti-prothrombin antibodies in recurrent spontaneous miscarriage. Eur J Obstet Gynecol Reprod Biol 2012, 163:170-174.
19. Galli M., Borrelli G., Jacobsen E.M., Marfisi R.M., Finazzi G., Marchioli R., et al. Clinical significance of different antiphospholipid antibodies in the WAPS study. Blood 2007, 110:1178-1183.
20. Alijotas-Reig J., Casellas-Caro M., Ferrer-Oliveras R., Llurba-Olive E., Hermosilla E., Vilardell-Tarres M., et al. Are anti-beta-glycoprotein-I antibodies markers for recurrent pregnancy loss in lupus anticoagulant/anticardiolipin seronegative women?. Am J Reprod Immunol 2008, 60:229-237.
21. Forastiero R. Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation. Lupus 2014, 23:1252-1254.
22. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006, 4:205-306.
23. Wilson W.A., Gharavi A.E., Koike T., Loskshin M.D., Branch D.W., Piette J.C., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of a international workshop. Arthritis Rheum 1999, 42:1309-1311.
24. Galarza-Maldonado C., Kourilovitch M.R., Perez-Fernandez O., Gaybor M., Cordero C., Cabrera S., et al. Obstetric antiphospholipid syndrome. Autoimmun Rev 2012, 11:288-295.
25. Alijotas-Reig J., Garrido-Gimenez C. Current concepts and new trends in the diagnosis and management of recurrent miscarriage. Obstet Gynecol Surv 2013, 68:445-466.
26. Negro R., Formoso G., Mangieri T., et al. Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab 2006, 91:2587-2591.
27. Opatrny L., David M., Kahn S.R., Shrier I., Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006, 33:2214-2221.
28. Saha S.P., Bhattacharjee N., Ganguli R.P., Sil S., Patra K.K., Sengupta M., et al. Prevalence and significance of antiphospholipid antibodies in selected at-risk obstetric cases: a comparative prospective study. J Obstet Gynaecol 2009, 29:614-618.
29. Matsubayashi H., Sugi T., Arai T., Kondo A., Suzuki T., Izumi S., et al. Different antiphospholipid antibody specificities are found in association with early repeated pregnancy loss versus IVF-failure patients. Am J Reprod Immunol 2001, 46:323-329.
30. Wong L.F., Porter T.F., de Jesus G.R. Recurrent early pregnancy loss and antiphospholipid antibodies: where do we stand?. Lupus 2014, 23:1226-1228.
31. Abou-Nassar K., Carrier M., Ramsay T., Rodger M.A. The association between antiphospholipid antibodies and placenta-mediated complications: a systematic review and meta-analysis. Thromb Res 2011, 128:77-85.
32. Silver R.M., Parker C.B., Reddy U.M., Goldenberg R., Coustan D., Dudley D.J., et al. Antiphospholipid antibodies and stillbirth. Obstet Gynecol 2013, 122:641-657.
33. Ferrer-Oliveras R., Llurba E., Cabero-Roura L., Alijotas-Reig J. Prevalence and clinical usefulness of antiphospholipid and anticofactor antibodies in different Spanish preeclampsia subsets. Lupus 2012, 21:257-263.
34. Pengo V., Banzato A., Denas G., Jose S.P., Hoxha A., Bison E., et al. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 2013, 12:832-834.
35. Clark C.A., Davidovits J., Spitzer K.A., Laskin C.A. The lupus anticoagulant: results from 2257 patients attending a high-risk pregnancy clinic. Blood 2013, 122:341-347.
36. Alijotas-Reig J., Ferrer-Oliveras R., llurba E., Farran-Codina I. Lupus anticoagulant and early recurrent miscarriage. Blood 2013, 122(e-letter).
37. Galli M., Luciani D., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in he antiphospholipid syndrome: a systematic review of the literature. Blood 2003, 101:1827-1832.
38. Lockshin M.D., Kim M., Laskin C.A., Guerra M., Branch D.W., Merill J., et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012, 64:2311-2318.
39. Devereese K.M. Antiphospholipid antibodies: evaluation of the thrombotic risk. Thromb Res 2012, 130:S37-S40.
40. Boffa M.C., Boinot C., De Carolis S., Rovere-Querini P., Aurousseau M.H., Allegri F., et al. Laboratory criteria of the obstetrical antiphospholipid syndrome (APS). Data from a multicentric prospective European women cohort. Thromb Haemost 2009, 102:25-28.
41. Ruffatti A., Salvan E., Del Ross T., Gerosa M., Andreoli L., Alijotas-Reig J., et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost 2014, 29(112):727-735.
42. Ruffati A., Calligaro A., Hoxha A., Trevisanuto D., Ruffatti T., Gervasi M.T., et al. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res 2010, 62:302-307.
43. Cervera R., Piette J.-C., Font J., Khamastha M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome. Arthritis Rheum 2002, 46:1019-1027.
44. Berman H., Ugarte-Gil M.F., Espinosa G., Tàssies D., Monteagudo J., Reverter J.C., et al. Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome?. Clin Exp Rheumatol 2013, 31:926-932.
45. Diz-Kucukkaya R., Hancer V.S., Artim-Esen B., Pekcelen Y., Inanc M. The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. J Thromb Thrombolysis 2010, 29:303-309.
46. Brouwer J.L., Bijl M., Veeger J.G.M., Kluin-Nelemans H.C., der Meer J. The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood 2004, 104:143-148.
47. Forastiero R., Martinuzzo M., Adamczuk Y., Varela M.L., Pombo G., Carreras L.O. The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome. Haematologica 2001, 86:735-741.
48. Berman H., Ugarte-Gil M.F., Espinosa G., Tassies D., Monteagudo J., Reverter J.C., et al. Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome. Clin Exp Rheumatol 2013, 31:926-932.